Core Viewpoint - PACS Group, Inc. is facing a class action securities lawsuit due to alleged securities fraud that has adversely affected its investors [1][2]. Class Definition - The lawsuit aims to recover losses for investors who purchased PACS Group's common stock during its initial public offering on April 11, 2024, and those who acquired securities between April 11, 2024, and November 5, 2024 [2]. Case Details - The complaint alleges that PACS Group engaged in fraudulent activities, including: 1. Submitting false Medicare claims that accounted for over 100% of the company's operating and net income from 2020 to 2023 [3]. 2. Billing for unnecessary respiratory and sensory integration therapies to Medicare [3]. 3. Falsifying documentation related to licensure and staffing [3]. 4. Making materially misleading statements about the company's business and prospects [3]. Next Steps - Investors who suffered losses during the relevant timeframe have until January 13, 2025, to request appointment as lead plaintiff, although participation does not require this role [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [5].

Core Viewpoint - A securities class action lawsuit has been filed against PACS Group, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial performance during the Class Period from April 11, 2024, to November 5, 2024 [1]. Allegations of Misconduct - The lawsuit claims that PACS engaged in a scheme to submit false Medicare claims, which accounted for over 100% of its operating and net income from 2020 to 2023 [3]. - It is alleged that PACS billed for thousands of unnecessary respiratory and sensory integration therapies to Medicare [3]. - The company is accused of falsifying documentation related to licensure and staffing [3]. - As a result of these actions, the positive statements made by PACS regarding its business and prospects were misleading and lacked a reasonable basis [3]. Lead Plaintiff Process - Investors in PACS have until January 13, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [4]. - A lead plaintiff acts on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [4]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [4].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of PACS Group, Inc. due to allegations of fraudulent activities that misled investors regarding the company's financial health and operations [1][3]. Group 1: Class Action Details - The class action is for individuals and entities that purchased PACS Group common stock during the initial public offering on April 11, 2024, and between April 11, 2024, and November 5, 2024 [2]. - Shareholders are encouraged to register for the class action by January 13, 2025, to potentially be appointed as lead plaintiffs [4]. Group 2: Allegations Against PACS Group - The complaint alleges that PACS Group engaged in a scheme to submit false Medicare claims, which accounted for over 100% of the company's operating and net income from 2020 to 2023 [3]. - Additional allegations include billing for unnecessary respiratory and sensory integration therapies to Medicare and falsifying documentation related to licensure and staffing [3]. - As a result of these actions, the company's positive statements about its business and prospects were deemed materially misleading [3]. Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights and ensuring companies adhere to responsible business practices [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PACS Group To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in PACS Group between (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's April 11, 2024 initial public offering ("IPO" or the "Offering"); and/or (b) securit ...

Class Action Lawsuit Against PACS Group - Investors with substantial losses have the opportunity to lead a securities fraud class action lawsuit against PACS Group Inc (NYSE: PACS) [1] - The class period for the lawsuit is from April 11, 2024, to November 5, 2024, with a lead plaintiff deadline of January 13, 2025 [1] - Investors are encouraged to contact the Law Offices of Howard G Smith to discuss their legal rights in this class action [1] Allegations Against PACS Group - The complaint alleges that PACS Group engaged in a scheme to submit false Medicare claims, which drove more than 100% of the company's operating and net income from 2020 to 2023 [2] - The company is accused of billing thousands of unnecessary respiratory and sensory integration therapies to Medicare [2] - PACS Group allegedly falsified documentation related to licensure and staffing [2] - As a result, the company's positive statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis [2] Participation in the Class Action - To be a member of the class action, no action is required at this time; investors may retain counsel of their choice or remain an absent member [3] - For more information or questions about the class action, investors can contact Howard G Smith, Esquire, of the Law Offices of Howard G Smith [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PACS Group, Inc. regarding a class action lawsuit due to alleged fraudulent activities during the company's operations from 2020 to 2023 [1]. Summary by Sections Class Period - The lawsuit pertains to individuals and entities that purchased PACS Group common stock during the class period, which includes shares acquired from the April 11, 2024 initial public offering and securities purchased between April 11, 2024, and November 5, 2024 [3]. Allegations - The complaint alleges that PACS Group engaged in a scheme involving: 1. Submission of false Medicare claims that accounted for over 100% of the company's operating and net income from 2020 to 2023 [4]. 2. Billing for unnecessary respiratory and sensory integration therapies to Medicare [4]. 3. Falsifying documentation related to licensure and staffing [4]. 4. Misleading statements regarding the company's business, operations, and prospects due to the aforementioned activities [4]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by January 13, 2025, to participate in the case without any cost or obligation [5]. Once registered, they will receive updates through a portfolio monitoring software [5]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions that inflated stock prices [6].

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against PACS Group, Inc. (NYSE: PACS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in PACS, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/pacs-group-inc. Investors have until January 13, 2025, to ask the Court to be appointed to lead t ...

Core Viewpoint - The PACS Group, Inc. is facing a class action lawsuit due to allegations of securities fraud related to its initial public offering and subsequent financial practices [1][4][5]. Company Overview - PACS Group operates skilled nursing and assisted living facilities in the United States [3]. IPO Details - PACS Group conducted its IPO on April 11, 2024, issuing approximately 21.4 million shares at an offering price of $21.00 per share, resulting in net proceeds of around $450 million [3]. Allegations of Misconduct - The lawsuit claims that PACS Group engaged in a scheme to submit false Medicare claims, which allegedly accounted for over 100% of its operating and net income from 2020 to 2023 [4]. - It is also alleged that PACS Group billed for unnecessary respiratory and sensory integration therapies to Medicare and falsified documentation related to licensure and staffing [4]. Impact of Allegations - Following the publication of a report by Hindenburg Research on November 4, 2024, which highlighted these allegations, PACS Group's stock price fell by more than 27% [5]. - On November 6, 2024, PACS Group announced a postponement of its third quarter 2024 earnings release and disclosed receiving civil investigative demands from the federal government, leading to an additional stock price drop of 38.7% [6]. Legal Process - Investors who purchased PACS Group securities during the class period have until January 13, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][7].

SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired PACS Group, Inc. (NYSE: PACS) (a) common stock in connection with the Company's April 11, 2024 initial public offering ("IPO"), or (b) securities between April 11, 2024 and November 5, 2024. PACS Group, through its subsidiaries, operates senior care facilities, skilled nursing facilities, and assisted living facilities in the Unit ...

LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 13, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of PACS Group, Inc. (“PACS Group” or the “Company”) (NYSE: PACS) investors who purchased: (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s April 11, 2024 initial public offering ...